posted
On July 1, 2015, the Company also entered into a consulting agreement with Simon Shah to provide research services with respect to market applications of the AAGP(TM) molecule. Mr. Shah received a three-year stock option for 600,000 shares of common stock at $0.10 per share subject to vesting.